MOLECULAR SIGNATURE OF CUTANEOUS PIGMENT TASKS ASSOCIATED WITH THE TGF-BETA - SMAD SIGNALING PATH

摘要

Method of characterization of skin pigment spot apparent or suspected in a human, comprises comparing expression levels, in skin samples form the spot and unwounded adjacent skin, of at least a dermal gene involved in transforming growth factor (TGF)-beta -SMAD signalization, where the gene is TGFBR2, TGFB1, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 or SOSTDC1. Independent claims are included for: (1) a method of evaluating the efficacy of a treatment of skin pigment spots comprising comparing expression levels, in skin samples form the spot and unwounded adjacent skin after such a spot, before and after treatment, of at least a dermal gene involved in the transforming growth factor (TGF)-beta -SMAD signalization; (2) an in vitro method for evaluating the efficacy of a treatment of skin pigment spots, comprising comparing, before and after treatment, the level of expression in a representative cellular model of the skin, of at least one dermal gene involved in the path of the TGF-beta - SMAD or the level of expression or activity of the expression product of the selected gene; (3) cosmetic method of treatment or prevention of skin pigment spot of non-pathological human skin comprising modulating the level of expression or activity of the gene involved in the TGF-beta -SMAD signalization, where the modulation is effected through the use of an antisense molecule, an small interfering (si)RNA, a microRNA, salvianolic acid B or an extract of Wen-pi-tang-Hab-Wu-ling-san; (4) use of a modulator of the expression level or activity of the expression product of the gene, for cosmetic applications in the treatment of non-pathological skin pigment spots, where the modulator is an antisense molecule, siRNA, a microRNA, demineralized bone powder, pioglitazone, 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5- ylmethylsulfanyl]- 2-methyl-phenoxy-acetic acid (GW0742), cristata, flavonoid, fenofibrate, oxymatrine, salvianolic acid B, 4-[4-(1,3-benzodioxol-5-yl)- 5-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide (SB-431542), an extract of Wen-pi-tang-Hab-Wu-ling-san, 3-deoxyglucosone (precursor of glycation end product), N-acetyl-seryl-aspartyl-lysyl-proline or tetrandrine; and (5) a modulator of the expression level or activity of the expression product of the deraml gene. ACTIVITY : Dermatological. MECHANISM OF ACTION : Gene expression modulator.